Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals

Antibody drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor surface receptor-targeting antibody with a highly cytotoxic molecule payload. They enable delivery of cytotoxic therapy more directly to tumor cells and minimize delivery to healthy tiss...

Descripción completa

Detalles Bibliográficos
Autores principales: McNamara, Blair, Chang, Yifan, Goreshnik, Ashley, Santin, Alessandro D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474218/
https://www.ncbi.nlm.nih.gov/pubmed/37663226
http://dx.doi.org/10.2147/IJWH.S400537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474218/
https://www.ncbi.nlm.nih.gov/pubmed/37663226
http://dx.doi.org/10.2147/IJWH.S400537

Ejemplares similares